MALAT1 and hilar cholangiocarcinoma: Shi et al. (2018) showed that MALAT1 in plasma has excellent specificity and sensitivity as a diagnostic biomarker of hilar cholangiocarcinoma (AUC, 0.860; sensitivity, 81.1%; specificity, 90.9%). Further, when PCAT1, MALAT1, along with CPS1-IT1 were combined, the sensitivity and specificity increased to 85.5% and 93.2%, respectively (Shi et al., 2018).